E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
General and serious infection of the body. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effect of high-dose intravenous vitamin C vs. placebo on a composite of death or persistent organ dysfunction – defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors – assessed at 28 days on intensive care unit (ICU) patients. |
|
E.2.2 | Secondary objectives of the trial |
To compare the effect of high-dose intravenous vitamin C vs. placebo on: 1)6-month mortality 2)6-month HRQoL 3)organ function (days 1, 2, 3, 4, 7, 10, 14, and 28 if in ICU) 4)global tissue dysoxia 5)occurrence of stage 3 acute kidney injury (KDIGO criteria) 6)Acute hemolysis as defined by: -clinician judgment of hemolysis, as recorded in the chart, OR -hemoglobin drop of at least 25 g/L within 24 hours of a dose of IMP + 2 of the following: ▪reticulocyte count >2 times upper limit of normal at clinical site lab ▪haptoglobin < lower limit of normal at clinical site lab ▪Indirect (unconjugated) bilirubin >2 times upper limit of normal at clinical site lab ▪Lactate dehydrogenase (LDH) >2 times upper limit of normal at clinical site lab Severe hemolysis: -hemoglobin < 75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells 7)hypoglycemia as defined as core lab-validated glucose level < 3.8 mmol/L •To assess baseline vitamin C levels |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
To ascertain the volume of distribution, clearance, and plasma concentration over a course of 96 hours of intravenous vitamin C 50 mg/kg of weight every 6 hours or matching placebo. |
|
E.3 | Principal inclusion criteria |
In both countries: 1) Patients ≥ 18 years old; 2) Admitted to the ICU with proven or suspected infection as the main diagnosis; 3) Currently treated with a continuous intravenous infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine);
In France: 5) Patient (or his representant) who has signed an informed and written consent; 6) Affiliation to a social security system or to an universal health coverage (Couverture Maladie Universelle, CMU); 7) Patients under guardianship or curatorship will be included; 8) Patients in case of simple emergency (legal definition) will be included.
|
|
E.4 | Principal exclusion criteria |
1) > 24 hours of ICU admission; 2) Known glucose-6-phosphate dehydrogenase (G6PD) deficiency; 3) Pregnancy; 4) Known allergy to vitamin C; or to one of the excipients in particular methyl parahydroxybenzoate (E218) or propyl (E216); 5) Known kidney stones within the past 1 year; 6) Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition; 7) Expected death or withdrawal of life-sustaining treatments within 48 hours; 8) Previously enrolled in this study; 9) Previously enrolled in a trial for which co-enrolment is not allowed (co-enrolment to be determined case by case).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome will be a composite of death or persistent organ dysfunction (defined as dependency on mechanical ventilation, renal replacement, or vasopressors) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
both assessed at 28 days. |
|
E.5.2 | Secondary end point(s) |
The secondary outcomes will include: 1) Persistent organ dysfunction-free days in ICU, up to day 28. 2) Mortality at 6 months. 3) HRQoL in 6-month survivors assessed by the EuroQol-5D (EQ-5D). This questionnaire is a standardised measure of health status developed to provide a simple, generic measure of health for clinical and economic appraisal. It is made up for two components; health state description and evaluation. The health status is measured in terms of five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale. See Figure 4. 4) Global tissue dysoxia assessed by serum lactate concentration.24 This will be assessed using liquid chromatography technique coupled with tandem mass spectrometry (LC-MS/MS). 5) Organ function (including renal function) assessed by the SOFA score (Table 1) (days 1, 2, 3, 4, 7, 10, 14, and 28); 6) Occurrence of stage 3 acute kidney injury as defined by KDIGO criteria18 daily; 7) Acute hemolysis as diagnosed by the clinical site team (daily); 8) Hypoglycemia
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
India |
New Zealand |
Saudi Arabia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
6 months after the last patient being randomized. 6-months after randomization, a follow-up call is done to measure quality of life if the participant is alive. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |